Pre-market top gainer: 4893.T Noile-Immune Biotech (JPX) jumps 19.88%: heavy volume signals trader interest

4893.T stock jumped 19.88% in pre-market trading to 205.00 JPY on 17 Mar 2026, led by a surge in volume to 3,973,900 shares versus an average of 418,715. The move puts Noile-Immune Biotech Inc. (4893.T) at a day high of 205.00 JPY and near its 52-week high of 214.00 JPY on the JPX market in Japan. Traders are pricing in short-term optimism while fundamentals show deep R&D spending and a strong cash cushion. Below we parse the drivers, technicals, valuation, and Meyka AI model forecasts for investors watching the top gainer in pre-market trade

4893.T stock pre-market snapshot

Noile-Immune Biotech Inc. (4893.T) is trading on JPX at 205.00 JPY, up 34.00 JPY (19.88%) from a previous close of 171.00 JPY. Volume is 3,973,900 versus an average of 418,715, giving a relative volume of 6.80, which signals unusual intraday interest.

Catalysts and why the price moved

There is no single public earnings release tied to the jump; market drivers appear to be heightened trading interest and momentum chasing in the biotechnology sector. The stock opened 182.00 JPY and ran to the day high 205.00 JPY, suggesting aggressive buy orders and short-covering in pre-market session.

Financials and valuation snapshot

4893.T shows a market cap of 7,794,295,200 JPY, EPS of -16.01 and a negative PE of -11.24, reflecting cumulative losses. Cash per share is 90.49 JPY and book value per share is 90.80 JPY, producing a price-to-book around 1.98. Revenue is effectively minimal; R&D intensity is high at 74.18% of reported revenue, which is typical for early-stage CAR-T developers.

Meyka AI rating and model forecast

Meyka AI rates 4893.T with a score of 64.92 out of 100 and assigns a B / HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of 140.72 JPY, implying -31.36% vs the current 205.00 JPY, and a yearly projection of 55.27 JPY, implying -73.05%. Forecasts are model-based projections and not guarantees.

Technical outlook and trading levels

Momentum indicators show mixed signals: RSI is 60.85, ADX 30.55 (strong trend), and MFI 83.37 (overbought), while Bollinger Bands upper band is 172.21 JPY, below the current print. Short-term resistance sits near the 52-week high 214.00 JPY and immediate support near the day low 175.00 JPY and the 50-day average 149.82 JPY.

Risks and opportunities for investors

Opportunity: Noile-Immune (4893.T) operates in CAR-T oncology, a high-reward biotech niche where positive clinical data or partnerships can re-rate share prices. Risk: the company posts recurring losses, EPS -16.01, thin revenues, and model forecasts indicate substantial downside if clinical progress stalls. The balance sheet shows a strong cash buffer, but the company remains R&D dependent.

Final Thoughts

4893.T stock leads pre-market top gainers on 17 Mar 2026 after a 19.88% rise to 205.00 JPY on unusually high volume. Short-term traders should note stretched technicals—MFI 83.37 and price above the Bollinger upper band—while long-term investors must weigh heavy R&D spending against a solid cash-per-share cushion (90.49 JPY). Meyka AI rates 4893.T 64.92 / 100 (B, HOLD) and flags model-based monthly and yearly forecasts of 140.72 JPY and 55.27 JPY respectively, implying downside from current levels. For active traders the key levels are 214.00 JPY resistance and 175.00 JPY support; for investors, clinical readouts and partnership news are the primary re-rating drivers. These views come from Meyka AI-powered market analysis platform and are informational only—forecasts are projections, not guarantees, and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.